Unknown

Dataset Information

0

ZPD-2, a Small Compound That Inhibits α-Synuclein Amyloid Aggregation and Its Seeded Polymerization.


ABSTRACT: α-Synuclein (α-Syn) forms toxic intracellular protein inclusions and transmissible amyloid structures in Parkinson's disease (PD). Preventing α-Syn self-assembly has become one of the most promising approaches in the search for disease-modifying treatments for this neurodegenerative disorder. Here, we describe the capacity of a small molecule (ZPD-2), identified after a high-throughput screening, to inhibit α-Syn aggregation. ZPD-2 inhibits the aggregation of wild-type α-Syn and the A30P and H50Q familial variants in vitro at substoichiometric compound:protein ratios. In addition, the molecule prevents the spreading of α-Syn seeds in protein misfolding cyclic amplification assays. ZPD-2 is active against different α-Syn strains and blocks their seeded polymerization. Treating with ZPD-2 two different PD Caenorhabditis elegans models that express α-Syn either in muscle or in dopaminergic (DA) neurons substantially reduces the number of α-Syn inclusions and decreases synuclein-induced DA neurons degeneration. Overall, ZPD-2 is a hit compound worth to be explored in order to develop lead molecules for therapeutic intervention in PD.

SUBMITTER: Pena-Diaz S 

PROVIDER: S-EPMC6928008 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

ZPD-2, a Small Compound That Inhibits α-Synuclein Amyloid Aggregation and Its Seeded Polymerization.

Peña-Díaz Samuel S   Pujols Jordi J   Conde-Giménez María M   Čarija Anita A   Dalfo Esther E   García Jesús J   Navarro Susanna S   Pinheiro Francisca F   Santos Jaime J   Salvatella Xavier X   Sancho Javier J   Ventura Salvador S  

Frontiers in molecular neuroscience 20191217


α-Synuclein (α-Syn) forms toxic intracellular protein inclusions and transmissible amyloid structures in Parkinson's disease (PD). Preventing α-Syn self-assembly has become one of the most promising approaches in the search for disease-modifying treatments for this neurodegenerative disorder. Here, we describe the capacity of a small molecule (ZPD-2), identified after a high-throughput screening, to inhibit α-Syn aggregation. ZPD-2 inhibits the aggregation of <i>wild-type</i> α-Syn and the A30P  ...[more]

Similar Datasets

| S-EPMC8139990 | biostudies-literature
| S-EPMC6902716 | biostudies-literature
| S-EPMC5882657 | biostudies-literature
| S-EPMC7855663 | biostudies-literature
| S-EPMC9209734 | biostudies-literature
| S-EPMC10808200 | biostudies-literature